Search

COOL therapy for cisplatin-induced hearing loss

Cisplatin is a commonly used cancer therapy, with nearly 50% of patients undergoing chemotherapy receiving cisplatin as part of their regimen [1]. Depending on the dose, incidence of hearing loss has been reported as 12-100% in adults, and 37-94% in...

Temporal bone trauma

Introduction Temporal bone injuries represent one of the more complex management problems presenting to the otolaryngologist. This is largely due to difficulties in assessment and the frequent delays in referral, often as a result of other injuries demanding more immediate...

Inter-professional teamwork and hearing care for older adults with cognitive loss

There is growing awareness that hearing loss is linked to dementia [1]. The average first-time hearing aid user is about 70 years old. By this age, approximately 1 in 2 people have hearing loss and 1 in 7 have cognitive...

Hearing in middle-age: hearing impairment, tinnitus and hearing aid use in UK adults

Hearing loss has a well-documented adverse impact on emotional, social and physical well-being. In this article, Dr Piers Dawes from the University of Manchester gives an insight into his team’s recent work analysing the very large UK Biobank data set,...

The challenge of disrupting the hearing care market in the USA

Barry Freeman, an Audiology Consultant of extensive global experience, examines the business model of hearing care service delivery in America. He discusses the challenges the profession has faced, and proposes some food for thought on learning from other health care...

In conversation with Reza Rahbar

Reza Rahbar is professor of otolaryngology at Harvard Medical School and associate otolaryngologist-in-chief at Boston Children’s Hospital. He initiated and leads IPOG, the International Pediatric Otolaryngology Group. I met up with him to ask more about it. Reza Rahbar DMD,...

ENT and evidence-based medicine: How do they benefit each other?

How do we assess evidence, and how should ENT surgeons use EBM? Evidence-based medicine (EBM) is the practice of medicine based upon high quality scientific research. There are several formal definitions of EBM, the most widely quoted being that of...

Systemic agents in thyroid cancer

For those patients who have disseminated or unresectable thyroid cancer, Dr Arabella Hunt and Dr Kate Newbold review systemic treatments, their differences, toxicities and outcomes. Thyroid cancer is the most common endocrine malignancy. It is subdivided into differentiated (papillary, follicular...

What’s the appetite for clinical risk?

The first Professor and Chair of Medical Professionalism at RCSI and BSHS, Dubhfeasa Slattery provides an overview of how a desire for better healthcare at all levels can be harnessed and nourished, leading to a potential life-long interest in reducing...

Developing outcome measures for research

There are challenges in developing outcomes measures; Professor Hall presents five top pointers for making rapid progress in developing outcome measures for research purposes. Anyone who has worked clinically with hearing loss will appreciate that every patient’s experience is personal....